Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome

OBJECTIVES: In the pivotal 24-week, phase III, placebo-controlled trial, teduglutide significantly reduced parenteral support (PS) requirements in patients with short bowel syndrome (SBS). STEPS-2 was a 2-year, open-label extension of that study designed to evaluate long-term safety and efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwartz, Lauren K, O'Keefe, Stephen J D, Fujioka, Ken, Gabe, Simon M, Lamprecht, Georg, Pape, Ulrich-Frank, Li, Benjamin, Youssef, Nader N, Jeppesen, Palle B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Contributions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4817413/
https://www.ncbi.nlm.nih.gov/pubmed/26844839
http://dx.doi.org/10.1038/ctg.2015.69

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4817413/
https://www.ncbi.nlm.nih.gov/pubmed/26844839
http://dx.doi.org/10.1038/ctg.2015.69

Ejemplares similares